Search

everythinglearnresearchcommunity

for

Search:↓

Treating hair loss in both men and women is effective and improves quality of life.

Trichoscopy helps diagnose and monitor hair and scalp problems without needing many biopsies.

More research is needed to standardize and prove the effectiveness of platelet-rich plasma treatments.

CCCA is a scarring hair loss condition mainly in African descent women, possibly caused by genetics and hairstyling, treated with gentle hair care and medications.

Specialized techniques are needed for hair restoration in individuals with curly Afrocentric hair due to unique challenges.

In the Middle Ages, European noblewomen intentionally removed forehead hair to be fashionable, showing how beauty standards can affect the perception of hair loss.

Dupilumab helped a woman with severe hair loss regrow her hair quickly and maintain it for six months after stopping treatment.

Secukinumab can cause hair loss, which may improve after stopping the medication.

Dermatologists should recognize diverse discoid lupus signs to avoid misdiagnosis.

Recognizing rare hair loss patterns in young females can improve understanding and treatment.

A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Anti-TNF-α therapy may increase the risk of developing alopecia areata, especially in those with a history of autoimmune disease.

Trichoscopy helps diagnose frontal fibrosing alopecia, even with unusual patterns.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

Leflunomide and anthralin may effectively treat severe alopecia areata.

The paper concludes that recognizing bitemporal alopecia areata is important for early treatment and preventing its progression.

Experts recommend starting systemic treatment for alopecia areata when the condition is severe or causes significant distress.

Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.

Most children with alopecia areata have patchy hair loss and common trichoscopic features like yellow and black dots.

There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.

The treatment is effective and safe for severe alopecia areata in children, but not for total or universal hair loss.

Oral tofacitinib successfully treated a girl's severe skin and hair conditions.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

About half of people with mild alopecia areata see hair regrowth in a year, but relapses are common.

Trichoscopy shows black dots, yellow dots, and empty follicles are common in Alopecia Areata, with broken and exclamation mark hair as typical patterns.

The document says how to diagnose and treat hair loss from alopecia areata, but there's no cure and treatments vary.

Alopecia Areata Incognita causes sudden hair loss in young females but usually has a better outcome than other types.

Alopecia areata in children shows varied forms and treatment challenges, with some achieving full or partial hair regrowth.

Alopecia areata is a hair loss condition that often starts before age 30 and can affect various body parts, with unpredictable hair regrowth chances.